<DOC>
	<DOCNO>NCT00003380</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy consist liposomal doxorubicin etoposide treat patient recurrent persistent ovarian , fallopian tube , peritoneal cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Etoposide Treating Patients With Recurrent Persistent Ovarian , Fallopian Tube , Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine optimal dose doxorubicin HCl liposomal prolonged oral etoposide patient recurrent persistent ovarian , tubal , peritoneal carcinoma . II . Determine nature degree toxicity therapy patient . III . Evaluate response rate patient measurable disease . OUTLINE : This dose escalation , multicenter study etoposide doxorubicin HCl liposome . Patients receive doxorubicin HCl liposome IV 1 hour day 1 , follow oral etoposide 8-14 day begin day 2 . For patient achieve partial complete response , treatment repeat every 4 week 1 year absence disease progression unacceptable toxicity . For patient stable disease , treatment repeat every 4 week 6 month . In absence dose limit toxicity ( DLT ) first 3 patient treat , subsequent cohort 3-6 patient receive dos etoposide prolong period . After 14 day oral etoposide , dose doxorubicin HCl liposome escalate . The maximum tolerate dose define dose precede 2 6 patient experience DLT . Patients follow every 3 month 1 year , death . PROJECTED ACCRUAL : A total 24 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent persistent ovarian , tubal , peritoneal carcinoma follow cell type : Serous adenocarcinoma Mucinous adenocarcinoma Clear cell adenocarcinoma Transitional cell Endometrioid adenocarcinoma Undifferentiated carcinoma Mixed epithelial carcinoma Malignant Brenner tumor Adenocarcinoma otherwise specify Must eligible high priority phase II phase III GOG protocol PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Granulocyte count least 1,500/mm3 Hepatic : Bilirubin great 1.5 time normal SGOT/SGPT/GGT great 2.5 time normal Alkaline phosphatase great 2.5 time normal No acute hepatitis Renal : Creatinine great 2.0 mg/dL Creatinine clearance great 50 mL/min Cardiovascular : LVEF within normal range determine MUGA No congestive heart failure unstable angina No myocardial infarction within past 6 month Prior abnormal cardiac conduction ( e.g. , bundle branch block , heart block ) allow stable least 6 month Other : No significant infection No septicemia Body surface area least 1 m2 Adequate intestinal function ( i.e. , require IV hydration nutritional support ) No severe gastrointestinal bleeding No invasive malignancy within past 5 year except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy recover Chemotherapy : Must receive least 1 prior cisplatinpaclitaxel base regimen At least 3 week since prior chemotherapy recover No prior anthracycline therapy Endocrine therapy : At least 3 week since prior endocrine therapy recover Radiotherapy : No prior radiotherapy 10 % bone marrow Surgery : At least 3 week since prior surgery recover</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>